Albireo Pharma - ALBO Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALBO shares.
View ALBO analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued twelve-month price objectives for Albireo Pharma's stock. Their ALBO share price forecasts range from $66.00 to $80.00. On average, they anticipate the company's share price to reach $72.67 in the next year. This suggests a possible upside of 189.4% from the stock's current price.
View analysts price targets for ALBO or view top-rated stocks among Wall Street analysts.

Albireo Pharma's stock was trading at $23.29 on January 1st, 2022. Since then, ALBO stock has increased by 7.8% and is now trading at $25.11.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our ALBO earnings forecast.

Albireo Pharma will be holding an earnings conference call on Monday, August 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing analysts' consensus estimates of ($2.02) by $0.17. The biopharmaceutical company had revenue of $6.83 million for the quarter, compared to analyst estimates of $7.82 million. Albireo Pharma had a negative net margin of 72.02% and a negative trailing twelve-month return on equity of 73.93%. During the same quarter last year, the business posted ($2.29) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Chicago Capital LLC (6.98%), Rice Hall James & Associates LLC (2.41%), Privium Fund Management B.V. (1.55%), MAI Capital Management (1.22%), Swiss National Bank (0.21%) and DekaBank Deutsche Girozentrale (0.18%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends.

Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALBO stock can currently be purchased for approximately $25.11.

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $486.18 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

The company employs 130 workers across the globe.

Albireo Pharma was founded in 2003.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.